Effects of an EEG neurofeedback intervention in cancer patients

Effects of an EEG neurofeedback intervention in cancer patients - Neuro-ID

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

DRKS

Registry ID

DRKS00015773

Enrollment

Registered

2018-10-23

Start date

2018-10-25

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F43.2 C00-C97

Interventions

Group 1: Neurofeedback-Paradigm: N = 40 Neurofeedback training will performed with the Mind Wave Headset (NeuroSky & Inc, 2011) and the electrode will be placed on Cz. The investigator will be presen

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patient with cancer diagnosis (all cancer types, all stages) will be included. The participant with provided informed consent. Age: 18-75 years.

Exclusion criteria

Exclusion criteria: Patients with major depression (F 32.2 or F33.3) or acute suicidality, patients with psychotic symptoms/diseases and/or central nervous system disease. A lack of language skills.

Design outcomes

Primary

Measure	Time frame
Alleviation of cognitive impairements of cancer patients. Instruments: •Functional Assessment of Cancer Therapy – Cognitive Function [FACT-Cog] (Bonomi et al., 1996) Measurement: t0 = inclusion in study t1 = after 5-week waitlist period/ before intervention t2 = after intervention	—

Secondary

Measure	Time frame
- Alleviation of psychological impairments of cancer patients (e.g. distress, fatique and general symptoms) Instruments: •Psycho-Onkologische Basisdokumentation [PO-Bado] (Herschbach et al., 2008) •Distress Thermometer (Mehnert et al., 2006) •Hornheider Screening Instrument [HIS] (Strittmatter et al., 2003) •Multidimensionales Fatigue-Inventar [MFI-20] (Smets et al., 1996) •Patient Health Questionnaire Depression Scale [PHQ-8] (Kroenke et al., 2009) •Generalized Anxiety Disorder Scale-7 [GAD-7] (Spitzer et al., 2006) •Ruminative Antwort Skala des Response Styles Questionnaire [RSQ] (Kuehner & Buerger, 2005) - changes in the alpha band power. - inceased quality of life: European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire [EORTC QLQ-C30] (Aaronson et al., 1993) measurement: t0 = inclusion in study t1 = after 5-week waitlist period/ before intervention t2 = after intervention	—

Measure

Time frame

- Alleviation of psychological impairments of cancer patients (e.g. distress, fatique and general symptoms) Instruments: •Psycho-Onkologische Basisdokumentation [PO-Bado] (Herschbach et al., 2008) •Distress Thermometer (Mehnert et al., 2006) •Hornheider Screening Instrument [HIS] (Strittmatter et al., 2003) •Multidimensionales Fatigue-Inventar [MFI-20] (Smets et al., 1996) •Patient Health Questionnaire Depression Scale [PHQ-8] (Kroenke et al., 2009) •Generalized Anxiety Disorder Scale-7 [GAD-7] (Spitzer et al., 2006) •Ruminative Antwort Skala des Response Styles Questionnaire [RSQ] (Kuehner & Buerger, 2005) - changes in the alpha band power. - inceased quality of life: European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire [EORTC QLQ-C30] (Aaronson et al., 1993) measurement: t0 = inclusion in study t1 = after 5-week waitlist period/ before intervention t2 = after intervention

—

Countries

Germany

Contacts

Public ContactMadeleine Fink

Klinik für Psychosomatische Medizin und Psychotherapie LVR-Klinikum Essen Kliniken / Institut der Universität Duisburg-Essen

madeleine.fink@uni-due.de0201-7227-208

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 10, 2026